Quantisnow Logo
Dashboard

BetterInvesting™ Magazine Update on Amphastar Pharmaceuticals Inc. and Medtronic PLC

$AMPH
$MDT
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $AMPH alert in real time by email

TROY, Mich., June 14, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) as its "Stock to Study" and Medtronic PLC (NYSE:MDT) as its "Undervalued Stock" in the September 2024 issue for investors' informational and educational use.

"With GameStop back in the headlines, the siren song of easy money has returned, luring the unschooled down treacherous paths. The National Association of Investors counsels everyday Americans seeking long term wealth to focus on fundamentals and learn to earn," said Ken Zendel, CEO of National Association of Investors Corp. (NAIC), the parent organization of BetterInvesting.

For a refresher on GameStop vs. the fundamentals, read:

https://www.betterinvesting.org/learn-about-investing/investor-education/investing/market-madness-short-selling-short-squeeze

Check the September 2024 issue of BetterInvesting Magazine for more details about the latest stocks. Non-members can utilize the limited, trial version of the BetterInvesting online stock selection and analysis tools to study the investment potential of Amphastar Pharmaceuticals and Medtronic by viewing their fundamental data and applying judgments.

Committee members are Dan Rutter, CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; and Anne Nichols, CFA; Lauren Adams, CFA.

As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

About BetterInvesting:

BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

Follow us on LinkedIn and Facebook.

Contact: 877-275-6242

Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-amphastar-pharmaceuticals-inc-and-medtronic-plc-302173374.html

SOURCE NAIC-BetterInvesting

Get the next $AMPH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AMPH
$MDT

CompanyDatePrice TargetRatingAnalyst
Medtronic plc.
$MDT
3/4/2025$92.00 → $107.00Neutral → Buy
Citigroup
Amphastar Pharmaceuticals Inc.
$AMPH
2/4/2025$66.00 → $36.00Overweight → Neutral
Piper Sandler
Amphastar Pharmaceuticals Inc.
$AMPH
11/22/2024$55.00Equal Weight
Wells Fargo
Medtronic plc.
$MDT
10/10/2024$98.00 → $105.00Sector Perform → Outperform
RBC Capital Mkts
Medtronic plc.
$MDT
8/21/2024$92.00 → $94.00Perform
Oppenheimer
Medtronic plc.
$MDT
8/15/2024$76.00 → $90.00Sell → Neutral
UBS
Medtronic plc.
$MDT
8/14/2024$100.00 → $85.00Buy → Hold
Stifel
Medtronic plc.
$MDT
5/30/2024$83.00Sell
Goldman
More analyst ratings

$AMPH
$MDT
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

  • Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

    GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. The findings were presented as late-breaking clinical science at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in the JACC, the flagship journal of the American College of Cardiology. The E

    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • CGS Transforms Workplace Training with Cicero, a New AI-Driven, Customizable Roleplay Platform

    NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- CGS Immersive™, the leader in enterprise learning that is modernizing training and development with AI and XR technologies, today introduced Cicero™, a hyper realistic roleplay application for upskilling workforces. Using AI-powered interactions, Cicero facilitates immersive roleplay using lifelike personas and real-time feedback in scenarios so realistic, it helps trainees to master the unexpected things that happen in real-life interactions with customers and other business contacts. The need for innovative learning and development programs has never been more urgent as technology is disrupting the regular course of business and workplace int

    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$AMPH
$MDT
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AMPH
$MDT
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AMPH
$MDT
 SEC Filings

See more

$AMPH
$MDT
 FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more

  • FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling

    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling

    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • FDA Approval for NALOXONE HYDROCHLORIDE issued to AMPHASTAR PHARMS INC

    Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling

    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AMPH
$MDT
 Leadership Updates

Live Leadership Updates

See more

  • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

  • Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

    Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

  • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

$AMPH
$MDT
 Financials

Live finance-specific insights

See more

  • Medtronic announces cash dividend for fourth quarter of fiscal year 2025

    GALWAY, Ireland, March 6, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on April 11, 2025, to shareholders of record at the close of business on March 28, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquart

    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • Medtronic reports third quarter fiscal 2025 financial results

    Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland, Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organicGAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7%Company reiterates full year revenue and EPS guidanceCardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) productsU.S. Centers for Medicare and Medic

    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

  • Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AMPH
$MDT
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more